Skip to main content
. 2017 Dec 11;6:44. doi: 10.1186/s40169-017-0175-0

Fig. 8.

Fig. 8

The Kaplan–Meier estimates of overall and progression-free survival (a, b respectively) in the intent-to-treat population for liposomal irinotecan (PEP02), irinotecan, and docetaxal

(Reproduced with permission from [69])